TCL Archive FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint. July 21, 2006
TCL Archive Pazdur: Registration Trials Run By Groups Need Same Rigor As Industry Trials March 25, 2011